Martina Chirra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Martina Chirra has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Ammar Sukari
The Barbara Ann Karmanos Cancer Institute 12 Detroit
9 shared publications - Andrew Elliott
Caris Life Sciences, Phoenix, USA
9 shared publications - Anthony Nicholas Karnezis
Department of Pathology and Laboratory Medicine, University of California, Davis, CA 95817, USA
9 shared publications - Chukwuemeka Ikpeazu
Department of Medicine, University of Miami School of Medicine, Miami, FL
9 shared publications - Dalia El-Gamal
Division of Hematology and Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati
9 shared publications - Dan P. Zandberg
UPMC Hillman Cancer Center, Pittsburgh, PA
9 shared publications
Latest Publications
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Purpose:Radioactive iodine–refractory papillary thyroid cancers (PTC) containing BRAF V600E mutations can be treated with BRAF/MEK inhibitors (BRAF/MEKi), but their effectiveness compared with tyrosine kinase inhibitors (TKI) and immunotherapy (IO) remains unclear. Therefore, we compared real-world survival and molecular/transcriptional signatures in patients with BRAF V600E–mutated (BRAF-mut) and BRAF wild-type (WT) PTC.Experimental Design:Thyroid tumor samples underwent DNA/RNA next-generation sequencing and immunohistochemistry at Caris Life Sciences. Tumor microenvironment (TME) cell fractions were estimated by RNA deconvolution using quanTIseq. Insurance claims data were used to infer real-world overall survival (OS) and time on treatment.Results:A total of 1,348 patients with differentiated thyroid cancer were identified; 81.8% were classified as PTC, of which 68.4% harbored a BRAF V600E mutation. TERT promoter mutations were the most common mutation in PTC (72%) and were more prevalent in BRAF-mut versus BRAF-WT. Mutations in NRAS, HRAS, and KRAS, as well as RET, BRAF, and ETV6 gene fusions, were predominantly found in BRAF-WT PTC. BRAF-mut PTC were more often PD-L1+ (33% vs. 18%, P < 0.001) and had significantly higher IFNγ scores. OS was not significantly different between patients with BRAF-mut versus BRAF-WT PTC. Systemic treatment (BRAF/MEKi, TKI, or IO) was not associated with significant differences in OS in BRAF-mut PTC, although there was a trend for longer OS in those treated with TKI compared with BRAF/MEKi or IO.Conclusions:BRAF-mut PTC is associated with a proinflammatory TME milieu compared with BRAF-WT PTC. However, in this limited dataset, treatment choice was not associated with differences in OS in BRAF-mut PTC.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Purpose:Radioactive iodine–refractory papillary thyroid cancers (PTC) containing BRAF V600E mutations can be treated with BRAF/MEK inhibitors (BRAF/MEKi), but their effectiveness compared with tyrosine kinase inhibitors (TKI) and immunotherapy (IO) remains unclear. Therefore, we compared real-world survival and molecular/transcriptional signatures in patients with BRAF V600E–mutated (BRAF-mut) and BRAF wild-type (WT) PTC.Experimental Design:Thyroid tumor samples underwent DNA/RNA next-generation sequencing and immunohistochemistry at Caris Life Sciences. Tumor microenvironment (TME) cell fractions were estimated by RNA deconvolution using quanTIseq. Insurance claims data were used to infer real-world overall survival (OS) and time on treatment.Results:A total of 1,348 patients with differentiated thyroid cancer were identified; 81.8% were classified as PTC, of which 68.4% harbored a BRAF V600E mutation. TERT promoter mutations were the most common mutation in PTC (72%) and were more prevalent in BRAF-mut versus BRAF-WT. Mutations in NRAS, HRAS, and KRAS, as well as RET, BRAF, and ETV6 gene fusions, were predominantly found in BRAF-WT PTC. BRAF-mut PTC were more often PD-L1+ (33% vs. 18%, P < 0.001) and had significantly higher IFNγ scores. OS was not significantly different between patients with BRAF-mut versus BRAF-WT PTC. Systemic treatment (BRAF/MEKi, TKI, or IO) was not associated with significant differences in OS in BRAF-mut PTC, although there was a trend for longer OS in those treated with TKI compared with BRAF/MEKi or IO.Conclusions:BRAF-mut PTC is associated with a proinflammatory TME milieu compared with BRAF-WT PTC. However, in this limited dataset, treatment choice was not associated with differences in OS in BRAF-mut PTC.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Supplemental Table 2. GSEA gene sets with significant nominal p-values and associated ranks, metric, and enrichment score (ES).
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Supplemental Table 2. GSEA gene sets with significant nominal p-values and associated ranks, metric, and enrichment score (ES).
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Supplemental Table 1. Median gene expression by PTC BRAF-V600E vs BRAF-WT.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Supplemental Table 1. Median gene expression by PTC BRAF-V600E vs BRAF-WT.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world overall survival (OS) in patients with BRAF-mut PTC treated with BRAF/MEKi, TKI or IO from Biopsy Date.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world overall survival (OS) in patients with BRAF-mut PTC treated with BRAF/MEKi, TKI or IO from Biopsy Date.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world survival (OS) associated with BRAF-V600E mutations in PTC by Biopsy Date.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world survival (OS) associated with BRAF-V600E mutations in PTC by Biopsy Date.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Correlation of PD-L1 RNA expression and PD-L1 IHC.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Correlation of PD-L1 RNA expression and PD-L1 IHC.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world survival (OS) associated with BRAF-V600E mutations in PTC.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Real-world survival (OS) associated with BRAF-V600E mutations in PTC.
- 16 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1110-1119
Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Purpose: Radioactive iodine–refractory papillary thyroid cancers (PTC) containing BRAF V600E mutations can be treated with BRAF/MEK inhibitors (BRAF/MEKi), but their effectiveness compared with tyrosine kinase inhibitors (TKI) and immunotherapy (IO) remains unclear. Therefore, we compared real-world survival and molecular/transcriptional signatures in patients with BRAF V600E–mutated (BRAF-mut) and BRAF wild-type (WT) PTC. Experimental Design: Thyroid tumor samples underwent DNA/RNA next-generation sequencing and immunohistochemistry at Caris Life Sciences. Tumor microenvironment (TME) cell fractions were estimated by RNA deconvolution using quanTIseq. Insurance claims data were used to infer real-world overall survival (OS) and time on treatment. Results: A total of 1,348 patients with differentiated thyroid cancer were identified; 81.8% were classified as PTC, of which 68.4% harbored a BRAF V600E mutation. TERT promoter mutations were the most common mutation in PTC (72%) and were more prevalent in BRAF-mut versus BRAF-WT. Mutations in NRAS, HRAS, and KRAS, as well as RET, BRAF, and ETV6 gene fusions, were predominantly found in BRAF-WT PTC. BRAF-mut PTC were more often PD-L1+ (33% vs. 18%, P < 0.001) and had significantly higher IFNγ scores. OS was not significantly different between patients with BRAF-mut versus BRAF-WT PTC. Systemic treatment (BRAF/MEKi, TKI, or IO) was not associated with significant differences in OS in BRAF-mut PTC, although there was a trend for longer OS in those treated with TKI compared with BRAF/MEKi or IO. Conclusions: BRAF-mut PTC is associated with a proinflammatory TME milieu compared with BRAF-WT PTC. However, in this limited dataset, treatment choice was not associated with differences in OS in BRAF-mut PTC.
- 16 January 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (6) , 1110-1119
Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer
Purpose: Radioactive iodine–refractory papillary thyroid cancers (PTC) containing BRAF V600E mutations can be treated with BRAF/MEK inhibitors (BRAF/MEKi), but their effectiveness compared with tyrosine kinase inhibitors (TKI) and immunotherapy (IO) remains unclear. Therefore, we compared real-world survival and molecular/transcriptional signatures in patients with BRAF V600E–mutated (BRAF-mut) and BRAF wild-type (WT) PTC. Experimental Design: Thyroid tumor samples underwent DNA/RNA next-generation sequencing and immunohistochemistry at Caris Life Sciences. Tumor microenvironment (TME) cell fractions were estimated by RNA deconvolution using quanTIseq. Insurance claims data were used to infer real-world overall survival (OS) and time on treatment. Results: A total of 1,348 patients with differentiated thyroid cancer were identified; 81.8% were classified as PTC, of which 68.4% harbored a BRAF V600E mutation. TERT promoter mutations were the most common mutation in PTC (72%) and were more prevalent in BRAF-mut versus BRAF-WT. Mutations in NRAS, HRAS, and KRAS, as well as RET, BRAF, and ETV6 gene fusions, were predominantly found in BRAF-WT PTC. BRAF-mut PTC were more often PD-L1+ (33% vs. 18%, P < 0.001) and had significantly higher IFNγ scores. OS was not significantly different between patients with BRAF-mut versus BRAF-WT PTC. Systemic treatment (BRAF/MEKi, TKI, or IO) was not associated with significant differences in OS in BRAF-mut PTC, although there was a trend for longer OS in those treated with TKI compared with BRAF/MEKi or IO. Conclusions: BRAF-mut PTC is associated with a proinflammatory TME milieu compared with BRAF-WT PTC. However, in this limited dataset, treatment choice was not associated with differences in OS in BRAF-mut PTC.
- Open Access
- 1 July 2020
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 5479-5489
First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research
Olaparib is currently approved in maintenance treatment of advanced ovarian cancer after response to first-line chemotherapy for breast related cancer antigens (BRCA) mutated patients. The use of this agent is based on data from SOLO1 study that observed a decreased risk of disease progression or death and a median progression-free survival about 36 months longer in case of therapy with olaparib. However, this trial recruited only patients with advanced stage ovarian cancer. The aim of this review is to retrace the available data in order to clarify the potential efficacy and feasibility of olaparib administration in newly diagnosed epithelial ovarian cancer also in early stages.
- 1 July 2020
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 5479-5489
Open AccessFirst-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research
Olaparib is currently approved in maintenance treatment of advanced ovarian cancer after response to first-line chemotherapy for breast related cancer antigens (BRCA) mutated patients. The use of this agent is based on data from SOLO1 study that observed a decreased risk of disease progression or death and a median progression-free survival about 36 months longer in case of therapy with olaparib. However, this trial recruited only patients with advanced stage ovarian cancer. The aim of this review is to retrace the available data in order to clarify the potential efficacy and feasibility of olaparib administration in newly diagnosed epithelial ovarian cancer also in early stages.